Novonesis A/S

NSIS B

DK0060336014

Specialty Chemicals

Real-time Estimate Cboe Europe Other stock markets 05:16:43 2024-04-19 am EDT			5-day change	1st Jan Change
385 ^DKK	+0.61%		-0.18%	+3.29%

Apr. 08	Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023	CI
Mar. 26	China to speed up 'new productive forces', vice president says	RE

Novozymes : Transactions under Novozymes’ stock buyback program

February 24, 2020 at 08:22 am EST

Novozymes A/S
Changes in company's own shares Transactions under Novozymes' stock buyback program

Please read the full announcement in the attached PDF

Attachment

2020_13_Stock_Buybackprogram_EN

Attachments:
2020_13_Stock_Buybackprogram_EN.pdf

Attachments

Original document
Permalink

Disclaimer

Novozymes A/S published this content on 24 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2020 13:21:10 UTC

Latest news about Novonesis A/S

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023	Apr. 08	CI
China to speed up 'new productive forces', vice president says	Mar. 26	RE
Nordic Shares Rose Thursday; Embracer Group Series B Topped Leaders	Mar. 21	DJ
Transcript : Novozymes A/S, 2024 Guidance/Update Call, Mar 21, 2024	Mar. 21
Novonensis expects 2024 adjusted EBITDA margin of 35%	Mar. 21	RE
Novonesis Provides Earnings Guidance for the Year 2024	Mar. 21	CI
Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development	Mar. 18	MT
Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG	Mar. 18	CI
FMC Partners With Novonesis in Canada for Biosolution Products	Mar. 12	MT
Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West	Mar. 07	CI
Novozymes A/S Announces Board Appointments	Mar. 04	CI
Transcript : Novozymes A/S - Shareholder/Analyst Call	Mar. 04
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030	Feb. 12	RE
Novozymes A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments	Feb. 08
Novozymes, Chr. Hansen Complete Merger Settlement	Feb. 02	MT
Transcript : Novozymes A/S, 2023 Earnings Call, Feb 01, 2024	Feb. 01
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	Jan. 29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	Jan. 28	CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals	Jan. 26	MT
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod	Dec. 20	MT
Global markets live: BAE Systems, Amazon, Take-Two, Shell, Pfizer...	Dec. 13
Celadon Pharma raises GBP2.0 million via placing	Dec. 12	AN
Novozymes-Chr. Hansen Merger Gets EU Nod After Proposed Asset Sale	Dec. 12	MT
Kerry Group Buys Novozymes, Chr. Hansen Assets for EUR150 Million	Dec. 12	DJ

Chart Novonesis A/S

Duration

Period

More charts

Company Profile

Novonesis A/S (formerly Novozymes A/S) is the world's leading producer of enzymes and microorganisms for industrial companies. Net sales break down by market as follows: - industry of cleaning and household maintenance products (28.5%); - bioenergy (24.8%); - food industry and human health (22.1%); - technical and cereal industries (12.8%): microorganisms used in the field of wastewater treatment, technical enzymes intended for the textile, leather, pulp and paper industries; - agriculture and animal feed industry (11.8%): enzymes used to improve the productivity and digestion of certain foods. Net sales are geographically distributed as follows: Denmark (1.3%), Europe/Middle East/Africa (33.5%), North America (33.9%), Asia/Pacific (18.5%) and Latin America (12.8%).

Sector

Specialty Chemicals

Calendar

2024-04-30 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments

February 08, 2024 at 09:18 am EST

More Strategies

Ratings for Novonesis A/S

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

382.7 DKK

Average target price

430.9 DKK

Spread / Average Target

+12.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Industrial Biotechnology Chemicals

	1st Jan change	Capi.
NOVONESIS A/S	+3.29%	25.41B
CATHAY BIOTECH INC.	-27.46%	3.21B
BORREGAARD ASA	+11.79%	1.73B
PUYANG HUICHENG ELECTRONIC MATERIAL CO., LTD.	-23.38%	547M
HENAN JINDAN LACTIC ACID TECHNOLOGY CO.,LTD.	-28.16%	374M
BIO-ON S.P.A.	-81.65%	216M
CHEMCON SPECIALITY CHEMICALS LIMITED	-13.90%	111M

Industrial Biotechnology Chemicals

Novonesis A/S

Equities

NSIS B

DK0060336014

Specialty Chemicals

Novozymes : Transactions under Novozymes’ stock buyback program

EPS Revisions